Provenance Record

High-quality Briefing covering a significant clinical trial result. 1,024 words is 24 over the 1,000-word Briefing cap — a borderline case that does not warrant rejection given the substantive quality. The article appropriately caveats the small sample size and conference-abstract-only status.

Read 5 of 6 source snapshots (medicalxpress.com returned HTTP 403 — no snapshot available). source-0.html.gz (sciencedaily.com): Confirmed NEOPRISM-CRC, 32 patients, 33 months, 0 relapses, 59% pCR, Kai-Keen Shiu title/quote, Yanrong Jiang title, Marnix Jansen title/quote, Christopher Burston patient story/quote verbatim. source-1.html.gz (ucl.ac.uk): Confirmed all same facts independently, plus 5 hospital names including Christie NHS Foundation Trust Manchester. source-2.html.gz (ecancer.org): Confirmed all trial facts independently. source-3.html.gz (insideprecisionmedicine.com): Confirmed ctDNA progression (24%→43%→58% after cycles 1-3→100% post-surgery), super/dynamic/poor molecular responder groups (6/11/8 patients), 100%/82%/0% pCR by group. source-5.html.gz (scitechdaily.com): Confirmed patient story, 5-year survival rates (90%/65%/10% by stage), all trial facts. medicalxpress.com (source-4): 403 blocked. Claim attributed to it ('25% relapse within 3 years under standard care') is confirmed in UCL News (source-1).

All quantitative claims verified: 32 patients, 33 months mean follow-up, 0 relapses, 59% pCR, 10-15% MMR subtype, 44,000 UK cases/year, ctDNA progression percentages 24/43/58/100%, molecular responder groups confirmed. All researcher names, titles, and quotes verified verbatim.

Excellent clinical trial Briefing. All claims verified against 5 of 6 sources; the one blocked source (medicalxpress.com) has its attributed claim confirmed in UCL News. APPROVE.